Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexa B Kimball

Showing results (171-180 of 230) with videos related to

Pageof 23
Sort By:
JAMA Dermatology|February 3, 2021
Pregnancy Outcomes in Women With Moderate-to-Severe Psoriasis From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)Alexa B Kimball, Lyn Guenther, Sunil Kalia, et al.
Journal of the American Academy of Dermatology|May 14, 2010
Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trialRichard G Langley, Steven R Feldman, Chenglong Han, et al.
Journal of the American Academy of Dermatology|July 5, 2020
Risk of COVID-19 in dermatologic patients receiving long-term immunomodulatory therapyZachary E Holcomb, Monica Rosales Santillan, Peyton C Morss-Walton, et al.
The Journal of Dermatological Treatment|December 7, 2007
Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasisDennis A Revicki, Mary Kaye Willian, Alan Menter, et al.
Dermatology and Therapy|January 6, 2024
Burden of Hidradenitis Suppurativa: A Systematic Literature Review of Patient Reported OutcomesAlexa B Kimball, Joslyn Kirby, John R Ingram, et al.
Dermatology and Therapy|March 9, 2023
Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled TrialAlexa B Kimball, Errol P Prens, Thierry Passeron, et al.
American Journal of Clinical Dermatology|November 30, 2010
Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trialAlexa B Kimball, Arielle G Bensimon, Annie Guerin, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 7, 2018
Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety DatabaseMegan E B Clowse, Angela E Scheuerle, Christina Chambers, et al.
Journal of the American Academy of Dermatology|October 25, 2011
Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasisAlexa B Kimball, Philippe Szapary, Ulrich Mrowietz, et al.
Aging Cell|September 29, 2020
Metabolic dysfunction in human skin: Restoration of mitochondrial integrity and metabolic output by nicotinamide (niacinamide) in primary dermal fibroblasts from older aged donorsJohn E Oblong, Amy Bowman, Holly A Rovito, et al.
Pageof 23

Showing results (171-180 of 230) with videos related to

Sort By:
Pageof 23
JAMA Dermatology|February 3, 2021
Pregnancy Outcomes in Women With Moderate-to-Severe Psoriasis From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)Alexa B Kimball, Lyn Guenther, Sunil Kalia, et al.
Journal of the American Academy of Dermatology|May 14, 2010
Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trialRichard G Langley, Steven R Feldman, Chenglong Han, et al.
Journal of the American Academy of Dermatology|July 5, 2020
Risk of COVID-19 in dermatologic patients receiving long-term immunomodulatory therapyZachary E Holcomb, Monica Rosales Santillan, Peyton C Morss-Walton, et al.
The Journal of Dermatological Treatment|December 7, 2007
Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasisDennis A Revicki, Mary Kaye Willian, Alan Menter, et al.
Dermatology and Therapy|January 6, 2024
Burden of Hidradenitis Suppurativa: A Systematic Literature Review of Patient Reported OutcomesAlexa B Kimball, Joslyn Kirby, John R Ingram, et al.
Dermatology and Therapy|March 9, 2023
Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled TrialAlexa B Kimball, Errol P Prens, Thierry Passeron, et al.
American Journal of Clinical Dermatology|November 30, 2010
Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trialAlexa B Kimball, Arielle G Bensimon, Annie Guerin, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 7, 2018
Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety DatabaseMegan E B Clowse, Angela E Scheuerle, Christina Chambers, et al.
Journal of the American Academy of Dermatology|October 25, 2011
Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasisAlexa B Kimball, Philippe Szapary, Ulrich Mrowietz, et al.
Aging Cell|September 29, 2020
Metabolic dysfunction in human skin: Restoration of mitochondrial integrity and metabolic output by nicotinamide (niacinamide) in primary dermal fibroblasts from older aged donorsJohn E Oblong, Amy Bowman, Holly A Rovito, et al.
Pageof 23